• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

From MGUS to Myeloma: Understanding and Interrupting Disease Progression

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases. Read More

Darolutamide Approved by FDA for Metastatic Castration-Sensitive Prostate Cancer

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial. Read More

June-July 2025: Upcoming NCPA Items for Pharmacy Teams

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

FDA Grants De Novo Authorization to 5-Year Breast Cancer Risk Prediction Device

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Clarity Breast’s FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies. Read More

‘Freedom From the Need’: A Pharmacist’s Journey from Constant Hemophilia B Treatment to Gene Therapy

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Chip Hailey, a 74-year-old pharmacist with hemophilia B, shares how gene therapy has liberated him from decades of challenging treatment and restored his independence. Read More

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Zongertinib shows promising efficacy and safety for HER2-mutant NSCLC, with a 71% response rate and low toxicity, paving the way for future treatments. Read More
« Older Entries
Next Entries »

Recent Content

  • Utilizing AI in Prostate Cancer Care and Management
  • KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
  • Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
  • Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
  • Op-Ed: Expand Patient Choice to Lower Medication Costs
  • Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
  • Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
  • Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
  • SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
  • GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT